{"protocolSection":{"identificationModule":{"nctId":"NCT06470191","orgStudyIdInfo":{"id":"SPH-B007-302"},"organization":{"fullName":"Shanghai Jiaolian Drug Research and Development Co., Ltd","class":"INDUSTRY"},"briefTitle":"A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.","officialTitle":"A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy."},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-31","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-17","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Shanghai Jiaolian Drug Research and Development Co., Ltd","class":"INDUSTRY"},"collaborators":[{"name":"Shanghai Pharmaceuticals Holding Co., Ltd","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy"},"conditionsModule":{"conditions":["Primary Membranous Nephropathy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":216,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"B007","type":"EXPERIMENTAL","interventionNames":["Drug: B007"]},{"label":"Cyclosporin Capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cyclosporin Capsules"]}],"interventions":[{"type":"DRUG","name":"B007","description":"B007： Subcutaneous injection was administered on days 1 and 15","armGroupLabels":["B007"]},{"type":"DRUG","name":"Cyclosporin Capsules","description":"Cyclosporin Capsules： Orally, 3.5 mg/kg/d；","armGroupLabels":["Cyclosporin Capsules"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"ORR（Overall Remission Rate）","timeFrame":"Approximately 2 years"}],"secondaryOutcomes":[{"measure":"CRR（Complete Remission Rate）","timeFrame":"Approximately 2 years"},{"measure":"PRR（Partial Remission Rate）","timeFrame":"Approximately 2 years"},{"measure":"Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Approximately 2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;\n2. Subjects with glomerular filtration rate（eGFR） ≥ 45 mL/min/1.73 m2.\n3. If taking Angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists/sodium-glucose cotransporter 2 inhibitors/endothelin inhibitors, a stable dose within 4 weeks before screening is required;\n4. Subjects with 24-hour elevated urinary protein in accordance with the prescribed conditions;\n5. Subjects whose laboratory test results meet the prescribed standards during the screening period;\n6. Subjects who have fully understood this study and voluntarily signed the informed consent form；\n7. Subjects who are able to follow the study protocol as judged by the investigator.\n\nExclusion Criteria:\n\n1. Subjects with secondary membranous nephropathy or primary membranous nephropathy whose pathological reports suggest concomitant crescent bodies;\n2. Subjects identified by the investigator as previously resistant to CD20 monoclonal antibody or cyclosporine;\n3. Subjects who have received medication prescribed for membranous nephropathy;\n4. Subjects with concomitant prescribed diseases;\n5. Subjects with a known history of severe allergic reactions to humanized monoclonal antibodies, or known allergies to any component of cyclosporine or B007;\n6. Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug;\n7. Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency or suffer from other acquired or congenital immunodeficiency diseases;\n8. Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment;\n9. Subjects with CD4+ T lymphocyte count \\< 400 cells/μL;\n10. Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug;\n11. For male subjects who have not been sterilized: those who do not consent to the use of barrier contraception during the study period and for at least 12 months after the last administration of the study drug, and who do not consent to the use of other contraceptive methods by their spouses;\n12. Other conditions unsuitable for participation in this study determined by the Investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Minghui Zhao","role":"CONTACT","phone":"0086- 010-66119025","email":"bdyyec@163.com"}],"locations":[{"facility":"Beijing Tsinghua Changgung Hospital","city":"Beijing","country":"China","contacts":[{"name":"Yuehong Li","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking university first hospital","city":"Beijing","country":"China","contacts":[{"name":"Minghui Zhao","role":"CONTACT"}],"geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Second Norman Bethune Hospital of Jilin University","city":"Chang chun","country":"China","contacts":[{"name":"Ping Luo","role":"CONTACT"}],"geoPoint":{"lat":42.74694,"lon":126.24667}},{"facility":"The First Affiliated Hospital of Dalian Medical University","city":"Dalian","country":"China","contacts":[{"name":"Hongli Lin","role":"CONTACT"}],"geoPoint":{"lat":38.91222,"lon":121.60222}},{"facility":"The First Affiliated Hospital, Sun Yat-sen University","city":"Guangzhou","country":"China","contacts":[{"name":"Wei Chen","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine","city":"Hangzhou","country":"China","contacts":[{"name":"Hua Li","role":"CONTACT"}],"geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"The First Affiliated Hospital, Zhejiang University School of Medicine","city":"Hangzhou","country":"China","contacts":[{"name":"Heng Li","role":"CONTACT"}],"geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Shandong Provincial Hospital","city":"Jinan","country":"China","contacts":[{"name":"Rong Wang","role":"CONTACT"}],"geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"The First Affiliated Hospital of Guangxi Medical University","city":"Nanning","country":"China","contacts":[{"name":"Zhenhua Yang","role":"CONTACT"}],"geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"Affiliated Hospital of Nantong University","city":"Nantong","country":"China","contacts":[{"name":"Xinzhong Huang","role":"CONTACT"}],"geoPoint":{"lat":32.03028,"lon":120.87472}},{"facility":"The Affiliated Hospital of Qingdao University","city":"Qingdao","country":"China","contacts":[{"name":"Guangqun Xing","role":"CONTACT"}],"geoPoint":{"lat":36.06488,"lon":120.38042}},{"facility":"Shengjing Hospital affiliated to China Medical University","city":"Shenyang","country":"China","contacts":[{"name":"Hua Zhou","role":"CONTACT"}],"geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Renmin Hospital of Wuhan University","city":"Wuhan","country":"China","contacts":[{"name":"Dingping Yang","role":"CONTACT"}],"geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Xi'an Daxing Hospital","city":"Xi'an","country":"China","contacts":[{"name":"Chengqun Zhao","role":"CONTACT"}],"geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"The Second Affiliated Hospital of Xingtai Medical college","city":"Xingtai","country":"China","contacts":[{"name":"Huixiao Zheng","role":"CONTACT"}],"geoPoint":{"lat":37.06306,"lon":114.49417}},{"facility":"Yantai Yuhuangding Hospital","city":"Yantai","country":"China","contacts":[{"name":"Peng Li","role":"CONTACT"}],"geoPoint":{"lat":37.47649,"lon":121.44081}},{"facility":"The First Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","country":"China","contacts":[{"name":"Junjun Zhang","role":"CONTACT"}],"geoPoint":{"lat":34.75778,"lon":113.64861}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000007674","term":"Kidney Diseases"},{"id":"D000015433","term":"Glomerulonephritis, Membranous"}],"ancestors":[{"id":"D000014570","term":"Urologic Diseases"},{"id":"D000052776","term":"Female Urogenital Diseases"},{"id":"D000005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"},{"id":"D000005921","term":"Glomerulonephritis"},{"id":"D000009393","term":"Nephritis"},{"id":"D000001327","term":"Autoimmune Diseases"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M10698","name":"Kidney Diseases","asFound":"Nephropathy","relevance":"HIGH"},{"id":"M18104","name":"Glomerulonephritis, Membranous","asFound":"Membranous Nephropathy","relevance":"HIGH"},{"id":"M9031","name":"Glomerulonephritis","relevance":"LOW"},{"id":"M17319","name":"Urologic Diseases","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M27093","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M14127","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M8399","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"},{"id":"M12338","name":"Nephritis","relevance":"LOW"},{"id":"M4629","name":"Autoimmune Diseases","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"T3704","name":"Membranous Nephropathy","asFound":"Membranous Nephropathy","relevance":"HIGH"},{"id":"T2525","name":"Glomerulonephritis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000016572","term":"Cyclosporine"},{"id":"D000003524","term":"Cyclosporins"}],"ancestors":[{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000935","term":"Antifungal Agents"},{"id":"D000000890","term":"Anti-Infective Agents"},{"id":"D000003879","term":"Dermatologic Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000065095","term":"Calcineurin Inhibitors"}],"browseLeaves":[{"id":"M18961","name":"Cyclosporine","asFound":"Collection","relevance":"HIGH"},{"id":"M6730","name":"Cyclosporins","asFound":"Collection","relevance":"HIGH"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M6252","name":"Clotrimazole","relevance":"LOW"},{"id":"M11796","name":"Miconazole","relevance":"LOW"},{"id":"M4254","name":"Antifungal Agents","relevance":"LOW"},{"id":"M4214","name":"Anti-Infective Agents","relevance":"LOW"},{"id":"M7074","name":"Dermatologic Agents","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M30452","name":"Calcineurin Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}